Five things for pharma marketers to know: Tuesday, October 6

1. The FDA approved Alkermes' Aristada (aripiprazole lauroxil), an injectable schizophrenia treatment. The long-acting drug is a generic version of Abilify, according to The Wall Street Journal. The agency in April approved four generic versions of Abilify.

2. Eighty percent of growth in net profits for 20 of the largest drugmakers came from price increases in the US, The Wall Street Journal reported. The newspaper's analysis follows ongoing attention on pharma companies that rely on price increases to boost revenue and profit. Lawmakers last week called for a subpoena of Valeant, which raised the prices of two drugs it acquired in February.

3. Spark Therapeutics said its experimental treatment for an inherited eye disease achieved the main goal in a Phase-III clinical trial and the company plans to submit the drug to the FDA next year, according to The New York Times. If approved, it would be the first gene therapy to receive FDA approval. Spark has not yet released the trial data.

4. The Department of Health and Human Services is considering plans to engage in value-based drug pricing, which would tie price to a treatment's performance, InsideHealthPolicy reported. Some companies, like Novartis, have said they are considering risk-based contracts for some of the drugs they market. These contracts would tie the price of the drug to how well it performs with the patient.

5. ICYMI: Some of the nation's largest payers, including Aetna, CVS Health and Molina Healthcare, told Reuters that Eli Lilly's and Boehringer Ingelheim's type-2 diabetes treatment Jardiance needs more data before the drug is widely covered. 


Next Article in Payers/Managed Markets